Abstract
SummaryThe 40th International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to the bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen receptor covalent antagonists (SERCAs), the discovery of immune-modulating effects of demethylating agents as well as the exact characterization and risk assessment of BRCA2 mutations of previously unknown significance. Pathological advances aimed at the molecular understanding of intratumoral heterogeneity and the evolution of lobular breast cancer. Beyond preclinical discoveries at the molecular level, clinical studies provided evidence on the duration of adjuvant bisphosphonate treatment and the use of the EndoPredict multigenomic assay to predict response to neoadjuvant chemo- and endocrine therapy. The SUCCESS A study reported that the prolonged adjuvant administration of zoledronic acid for 5 years did not improve patient survival after chemotherapy. A translational analysis of the ABCSG 34 trial revealed that the EndoPredict multigenomic assay could identify patients who do not benefit from neoadjuvant endocrine or chemotherapy. These recent advances are likely to promote individualized breast cancer care.
Highlights
Several presentations of the 40th San Antonio Breast Cancer Symposium pointed out new possibilities to transfer findings in molecular biology into individualized patient care
In the course of disease progression, approximately 30% of breast cancers bearing resistance to endocrine therapy acquire mutations of the ESR1 gene that codes for estrogen receptor (ER) [1]
One clinical trial that is likely to influence clinical practice was the SUCCESS A study presented by Wolfgang Janni [8]. This phase III trial investigated whether the extended duration of zoledronic acid treatment from 2 to 5 years after adjuvant chemotherapy could increase survival in patients with high risk of breast cancer recurrence
Summary
Several presentations of the 40th San Antonio Breast Cancer Symposium pointed out new possibilities to transfer findings in molecular biology into individualized patient care. In the course of disease progression, approximately 30% of breast cancers bearing resistance to endocrine therapy acquire mutations of the ESR1 gene that codes for ER [1]. In the Mayo Clinic, Couch and colleagues developed a cellbased homology directed repair assay that can test the functionality of the BRCA2 protein.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.